Nombre del producto:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

CAS:916420-27-4
Fórmula molecular:C12H15Cl2N3O2
Pureza:95%+
Número de catálogo:CM104183
Peso molecular:304.17

Unidad de embalaje Stock disponible Precio($) Cantidad
CM104183-5g in stock ŌǸ
CM104183-10g in stock ƴijƴ
CM104183-25g in stock ħƚħ
CM104183-100g in stock ǙŮƈ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :916420-27-4
Fórmula molecular:C12H15Cl2N3O2
Punto de fusión:-
Código de sonrisas:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1
Densidad:
Número de catálogo:CM104183
Peso molecular:304.17
Punto de ebullición:
Nº Mdl:MFCD09025732
Almacenamiento:

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products